Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$179.9MCash, Jun 2026
33moCash Runway (est.)
+30%Share Count, 1 Year
Follow CMPX by emailGet an email when CMPX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CMPX, unsubscribe in one click. Privacy
📣 What CMPX Says Is Next
Q4 2026 · “CTX-10726 (PD-1 x VEGF-A bispecific antibody) The first patients have been dosed in the Phase 1 study, and the study is actively enrolling, with initial clinical data expected in Q4 2026.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “Additional data from the cohort expansions are expected in Q4 2026.”
Company press release, Aug 6, 2026 · SEC filing
Q4 · “The first patients in the Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) have been dosed and the study is actively enrolling, with initial data expected in Q4.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
CMPX reported $179.9M in cash and short-term investments (as of Jun 30, 2026) and used about $16.1M/quarter in operations, an estimated runway of 33.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:39 · Moderate
Cash runway 33 months
ATM program on file since Dec 2025 +15
Shelf registration (S-3, Dec 2025) +10
Share count +30% in a year +14
Recent financing filings on SEC EDGAR:
Dec 30, 2025 · Shelf registration with ATM program, up to $100M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMPX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.